Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
Authors
Keywords
AGEs, RAGE, Incretin, DPP-4, Oxidative stress
Journal
Cardiovascular Diabetology
Volume 14, Issue 1, Pages 2
Publisher
Springer Nature
Online
2015-01-12
DOI
10.1186/s12933-015-0176-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
- (2014) Annayya R. Aroor et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- LR-90 prevents methylglyoxal-induced oxidative stress and apoptosis in human endothelial cells
- (2014) James L. Figarola et al. APOPTOSIS
- Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression
- (2014) Yuji Ishibashi et al. Cardiovascular Diabetology
- Advanced glycation endproducts trigger autophagy in cadiomyocyte Via RAGE/PI3K/AKT/mTOR pathway
- (2014) Xuwei Hou et al. Cardiovascular Diabetology
- Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice
- (2014) Lin Zhu et al. Cardiovascular Diabetology
- Molecular Imaging of Vascular Inflammation
- (2014) Nobuhiro Tahara et al. CURRENT PHARMACEUTICAL DESIGN
- Role of AGEs-RAGE System in Cardiovascular Disease
- (2014) Kei Fukami et al. CURRENT PHARMACEUTICAL DESIGN
- Ratio of Serum Levels of AGEs to Soluble Form of RAGE Is a Predictor of Endothelial Function
- (2014) Masato Kajikawa et al. DIABETES CARE
- The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
- (2014) Angelo Avogaro et al. DIABETES CARE
- Molecular mechanisms of diabetic cardiomyopathy
- (2014) Heiko Bugger et al. DIABETOLOGIA
- Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis
- (2014) S. Nakashima et al. HORMONE AND METABOLIC RESEARCH
- Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity
- (2014) Sho-ichi Yamagishi et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Diabetes, aging, and their tissue complications
- (2014) Rick Bucala JOURNAL OF CLINICAL INVESTIGATION
- The potential for renoprotection with incretin-based drugs
- (2014) Tetsuhiro Tanaka et al. KIDNEY INTERNATIONAL
- Sulforaphane inhibits advanced glycation end product–induced pericyte damage by reducing expression of receptor for advanced glycation end products
- (2014) Sayaka Maeda et al. NUTRITION RESEARCH
- Effect of advanced glycation end product intake on inflammation and aging: a systematic review
- (2014) Katrien Van Puyvelde et al. NUTRITION REVIEWS
- ICAM-1 signaling in endothelial cells
- (2014) Charlotte Lawson et al. Pharmacological Reports
- Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells
- (2014) Mariola Dorecka et al. Pharmacological Reports
- Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways
- (2014) Karina Huynh et al. PHARMACOLOGY & THERAPEUTICS
- Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus
- (2014) Michael H. Davidson POSTGRADUATE MEDICINE
- Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study
- (2014) Lancet Diabetes & Endocrinology
- Pigment epithelium-derived factor (PEDF) binds to caveolin-1 and inhibits the pro-inflammatory effects of caveolin-1 in endothelial cells
- (2013) Takanori Matsui et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
- (2013) Yuji Ishibashi et al. Cardiovascular Diabetology
- Cellular signalling of the receptor for advanced glycation end products (RAGE)
- (2013) Jianling Xie et al. CELLULAR SIGNALLING
- Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both?
- (2013) Helen Vlassara et al. Current Diabetes Reports
- Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease
- (2013) Micheal S Ward et al. CURRENT OPINION IN PHARMACOLOGY
- Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction
- (2013) Ryotaro Ando et al. Diabetes & Vascular Disease Research
- The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
- (2013) David M. Nathan et al. DIABETES CARE
- Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
- (2013) Catherine L. Martin et al. DIABETES CARE
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
- (2013) Koji Sakata et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Advanced glycation end products: role in pathology of diabetic cardiomyopathy
- (2013) Vijaya Lakshmi Bodiga et al. HEART FAILURE REVIEWS
- The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes
- (2013) T-I Lee et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: A “glycoxidation-centric” point of view
- (2013) N.C. Chilelli et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Beneficial Effects of Vildagliptin on Retinal Injury in Obese Type 2 Diabetic Rats
- (2013) Satoshi Maeda et al. OPHTHALMIC RESEARCH
- Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression
- (2012) Ayako Ojima et al. AMERICAN JOURNAL OF PATHOLOGY
- The Effect of Excess Weight Gain With Intensive Diabetes Mellitus Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes Mellitus
- (2012) Jonathan Q. Purnell et al. CIRCULATION
- Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans
- (2012) Nobuhiro Tahara et al. CLINICAL BIOCHEMISTRY
- Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
- (2012) Sho-ichi Yamagishi et al. CURRENT PHARMACEUTICAL DESIGN
- Positive Association Between Serum Level of Glyceraldehyde-Derived Advanced Glycation End Products and Vascular Inflammation Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomography
- (2012) N. Tahara et al. DIABETES CARE
- Diabetes and life expectancy among Japanese – NIPPON DATA80
- (2012) Tanvir Chowdhury Turin et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Glucose-dependent Insulinotropic Polypeptide (GIP) Inhibits Signaling Pathways of Advanced Glycation End Products (AGEs) in Endothelial Cells via its Antioxidative Properties
- (2012) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats
- (2012) Sayaka Maeda et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
- (2012) Yuji Ishibashi et al. MICROVASCULAR RESEARCH
- A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats
- (2011) Atul Sureshrao Akarte et al. BIOCHEMICAL PHARMACOLOGY
- Serum Levels of Advanced Glycation End Products (AGEs) are Inversely Associated with the Number and Migratory Activity of Circulating Endothelial Progenitor Cells in Apparently Healthy Subjects
- (2011) So Ueda et al. Cardiovascular Therapeutics
- Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
- (2011) Sho-ichi Yamagishi CURRENT DRUG TARGETS
- Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes: Potential role of AGER1 and SIRT1
- (2011) J. Uribarri et al. DIABETES CARE
- Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus
- (2011) E. T. Rhodes et al. DIABETIC MEDICINE
- Sitagliptin Augments Protective Effects of GLP-1 against Advanced Glycation End Product Receptor Axis in Endothelial Cells
- (2011) Y. Ishibashi et al. HORMONE AND METABOLIC RESEARCH
- Effects of DPP-4 inhibition on cardiac metabolism and function in mice
- (2011) M. Lenski et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level
- (2011) Yuji Ishibashi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- AGE restriction in diabetes mellitus: a paradigm shift
- (2011) Helen Vlassara et al. Nature Reviews Endocrinology
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis
- (2011) Takanori Matsui et al. PHARMACOLOGICAL RESEARCH
- Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy—Friend or foe?
- (2011) Sho-ichi Yamagishi et al. PHARMACOLOGICAL RESEARCH
- Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies
- (2010) Robert Chilton et al. AMERICAN JOURNAL OF MEDICINE
- Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A
- (2010) Hisko Oeseburg et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15
- (2010) A. Puddu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Deletion of the Receptor for Advanced Glycation End Products Reduces Glomerulosclerosis and Preserves Renal Function in the Diabetic OVE26 Mouse
- (2010) Nina Reiniger et al. DIABETES
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- The cardiorenal syndrome in diabetes mellitus
- (2010) Hussein H. Karnib et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease
- (2010) Hiroki Ueno et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-κB activation
- (2010) Yuichiro Ide et al. MICROVASCULAR RESEARCH
- Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy
- (2010) Sho-ichi Yamagishi et al. Oxidative Medicine and Cellular Longevity
- Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2
- (2009) Qin Chen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
- (2009) Yuji Ishibashi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- On the origin of serum CD26 and its altered concentration in cancer patients
- (2009) Oscar J. Cordero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Impact of glucagon-like peptide-1 on endothelial function
- (2009) Sjöholm DIABETES OBESITY & METABOLISM
- Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy
- (2009) S. D. Ye et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Positive association of serum levels of advanced glycation end products and high mobility group box–1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients
- (2009) Tsukasa Nakamura et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Oral Glycotoxins Determine the Effects of Calorie Restriction on Oxidant Stress, Age-Related Diseases, and Lifespan
- (2008) Weijing Cai et al. AMERICAN JOURNAL OF PATHOLOGY
- Inflammation at the Molecular Interface of Atherogenesis
- (2008) Brian D. Lamon et al. AMERICAN JOURNAL OF PATHOLOGY
- Advanced Glycation End Product Homeostasis
- (2008) Helen Vlassara et al. Annals of the New York Academy of Sciences
- Metalloproteinase Expression in Monocytes and Macrophages and its Relationship to Atherosclerotic Plaque Instability
- (2008) Andrew C. Newby ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Inflammation and Plaque Vulnerability
- (2008) Prediman K. Shah CARDIOVASCULAR DRUGS AND THERAPY
- Role of Oxidative Stress in the Development of Vascular Injury and its Therapeutic Intervention by Nifedipine
- (2008) Sho-ichi Yamagishi et al. CURRENT MEDICINAL CHEMISTRY
- Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
- (2008) Michel Hoenig et al. CURRENT MOLECULAR MEDICINE
- Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
- (2008) Sho-ichi Yamagishi et al. CURRENT PHARMACEUTICAL DESIGN
- Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication
- (2008) Sho-ichi Yamagishi et al. CURRENT PHARMACEUTICAL DESIGN
- Possible Involvement of Advanced Glycation End-Products (AGEs) in the Pathogenesis of Alzheimers Disease
- (2008) Masayoshi Takeuchi et al. CURRENT PHARMACEUTICAL DESIGN
- Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications
- (2008) Sho-ichi Yamagishi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)
- (2008) Angela Raucci et al. FASEB JOURNAL
- The “Metabolic Memory”: Is More Than Just Tight Glucose Control Necessary to Prevent Diabetic Complications?
- (2008) Antonio Ceriello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers
- (2008) S. Yamagishi et al. MEDICAL HYPOTHESES
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
- (2008) W. Kim et al. PHARMACOLOGICAL REVIEWS
- Final Common Molecular Pathways of Aging and Cardiovascular Disease
- (2007) Francesco Cosentino et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes
- (2007) Kazuo Nakamura et al. MICROVASCULAR RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started